BRPI0810653A2 - Derivados de ácido nicotínico como moduladores do receptor metabotrópico de glutamato-5. - Google Patents

Derivados de ácido nicotínico como moduladores do receptor metabotrópico de glutamato-5.

Info

Publication number: BRPI0810653A2
Authority: BR; Brazil
Prior art keywords: glutamat; modulators; acid derivatives; nicotinic acid; metabotropic receptor
Prior art date: 2007-04-19

Application number

BRPI0810653-3A2A

Other languages

English (en)

Inventor

Ralf Glatthar

David Carcache

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-19

Filing date

2008-04-17

Publication date

2014-11-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38654771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0810653(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-04-17 Application filed by Novartis Ag filed Critical Novartis Ag

2014-11-04 Publication of BRPI0810653A2 publication Critical patent/BRPI0810653A2/pt

Links

PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title 1
102000006239 metabotropic receptors Human genes 0.000 title 1
108020004083 metabotropic receptors Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0810653-3A2A 2007-04-19 2008-04-17 Derivados de ácido nicotínico como moduladores do receptor metabotrópico de glutamato-5. BRPI0810653A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07106537		2007-04-19
PCT/EP2008/054682 WO2008128968A1 (en)	2007-04-19	2008-04-17	Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5

Publications (1)

Publication Number	Publication Date
BRPI0810653A2 true BRPI0810653A2 (pt)	2014-11-04

Family

ID=38654771

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0810653-3A2A BRPI0810653A2 (pt)	2007-04-19	2008-04-17	Derivados de ácido nicotínico como moduladores do receptor metabotrópico de glutamato-5.

Country Status (15)

Country	Link
US (1)	US20090105266A1 (pt)
EP (1)	EP2146969A1 (pt)
JP (1)	JP2010524892A (pt)
KR (1)	KR20090130141A (pt)
CN (1)	CN101679299A (pt)
AR (1)	AR068072A1 (pt)
AU (1)	AU2008240790A1 (pt)
BR (1)	BRPI0810653A2 (pt)
CA (1)	CA2682676A1 (pt)
CL (1)	CL2008001114A1 (pt)
EA (1)	EA200901379A1 (pt)
MX (1)	MX2009011208A (pt)
PE (1)	PE20090074A1 (pt)
TW (1)	TW200904425A (pt)
WO (1)	WO2008128968A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0606774D0 (en) *	2006-04-03	2006-05-10	Novartis Ag	Organic compounds
WO2010135493A2 (en) *	2009-05-20	2010-11-25	Emory University	Alzheimer's disease imaging agents
EP2390245A1 (en) *	2010-05-26	2011-11-30	Nabriva Therapeutics AG	Enantiomerically pure amines
AU2012232711B2 (en) *	2011-03-18	2016-04-28	Novartis Ag	Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
WO2013081094A1 (ja) *	2011-11-30	2013-06-06	東レ株式会社	イミダゾ［１，２－ａ］ピリジン誘導体及びその医薬用途
WO2013138617A1 (en)	2012-03-16	2013-09-19	Axikin Pharmaceuticals, Inc.	3,5-diaminopyrazole kinase inhibitors
WO2014151630A2 (en)	2013-03-15	2014-09-25	Irm Llc	Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en)	2013-03-15	2016-03-29	Novartis Ag	Compounds and compositions for the treatment of parasitic diseases
WO2014151729A1 (en)	2013-03-15	2014-09-25	Irm Llc	Compounds and compositions for the treatment of parasitic diseases
CA2917262A1 (en)	2013-07-02	2015-01-08	Syngenta Participations Ag	Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
BR112016014004B1 (pt)	2013-12-19	2022-11-01	Novartis Ag	Compostos para tratamento de doenças parasíticas, seus usos, e composições farmacêuticas
CN107074846B (zh)	2014-08-12	2020-05-19	先正达参股股份有限公司	具有含硫取代基的杀有害生物活性杂环衍生物
ES2806598T3 (es)	2014-12-11	2021-02-18	Syngenta Participations Ag	Derivados tetracíclicos activos como plaguicidas con sustituyentes que contienen azufre
TWI703133B (zh)	2014-12-23	2020-09-01	美商艾克斯基製藥公司	３,５-二胺基吡唑激酶抑制劑
ES2806459T3 (es)	2015-04-24	2021-02-17	Syngenta Participations Ag	Derivados policíclicos activos como plaguicidas con heterociclos con anillos de cinco miembros sustituidos con azufre
CN108040481B (zh)	2015-04-24	2020-10-30	先正达参股股份有限公司	具有硫取代的五元环杂环的杀有害生物活性多环衍生物
WO2017001314A1 (en)	2015-07-01	2017-01-05	Syngenta Participations Ag	Pesticidally active polycyclic derivatives with sulfur containing substituents
JP2018524337A (ja)	2015-07-01	2018-08-30	シンジェンタパーティシペーションズアーゲー	硫黄含有置換基を有する有害生物防除に活性な四環式誘導体
US11214565B2 (en)	2015-11-20	2022-01-04	Denali Therapeutics Inc.	Compound, compositions, and methods
BR112018010347A2 (pt)	2015-11-23	2018-12-04	Syngenta Participations Ag	derivados heterocíclicos ativos em termos pesticidas com substituintes contendo enxofre e ciclopropila
US11028080B2 (en)	2016-03-11	2021-06-08	Denali Therapeutics Inc.	Substituted pyrimidines as LRKK2 inhibitors
SMT202100699T1 (it)	2016-06-16	2022-01-10	Denali Therapeutics Inc	Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi
BR112019008492B1 (pt)	2016-10-27	2024-01-30	Syngenta Participations Ag	Compostos derivados heterocíclicos ativos em termos pesticidas com substituintes contendo enxofre e hidroxilamina, composição pesticida, método para controle de pragas e método para a proteção de material de propagação de plantas do ataque por pragas
WO2018091389A1 (en)	2016-11-17	2018-05-24	Syngenta Participations Ag	Pesticidally active heterocyclic derivatives with sulphur containing substituents
EP3554242A1 (en)	2016-12-15	2019-10-23	Syngenta Participations AG	Pesticidally active heterocyclic derivatives with sulfur containing substituents
JP7227157B2 (ja)	2016-12-29	2023-02-21	フェーズバイオファーマシューティカルズ，インコーポレイテッド	金属酵素阻害剤化合物
EP3562306B1 (en) *	2016-12-29	2025-02-26	Ji Xing Pharmaceuticals Hong Kong Limited	Metalloenzyme inhibitor compounds
MX388196B (es)	2017-04-26	2025-03-19	Basilea Pharm Int Ag	Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
WO2018215304A1 (en)	2017-05-22	2018-11-29	Syngenta Participations Ag	Tetracyclic pyridazine sulphur containing compounds and their use as pesticides
EP3634420A1 (en)	2017-06-06	2020-04-15	Urovant Sciences GmbH	Use of vibegron to treat overactive bladder
CN110891949B (zh)	2017-07-05	2023-05-23	先正达参股股份有限公司	具有含硫取代基的杀有害生物活性杂环衍生物
EP3798212A4 (en) *	2018-05-22	2022-03-23	Nihon Nohyaku Co., Ltd.	BENZIMIDAZOLE COMPOUND OR SALT THEREOF, INSECTICIDE AND ACARICIDE FOR AGRICULTURE AND HORTICULTURE WITH THIS COMPOUND AND METHODS OF USE
PY1943991A (es)	2018-06-06	2020-03-09	Syngenta Crop Protection Ag	Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
WO2019243523A1 (en)	2018-06-21	2019-12-26	Cellestia Biotech Ag	Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts
JP2022516969A (ja)	2019-01-08	2022-03-03	フェーズバイオファーマシューティカルズ，インコーポレイテッド	金属酵素阻害剤化合物
US20220185797A1 (en) *	2019-03-25	2022-06-16	The Trustees Of Columbia Universityin The City Of New York	Selective foxo inhibitors for treatment of diabetes and other disorders related to impaired pancreatic function
BR112021020226A2 (pt) *	2019-04-10	2021-12-07	Cellestia Biotech Ag	Inibidores de via de sinalização notch e uso dos mesmos no tratamento de cânceres
US11618751B1 (en)	2022-03-25	2023-04-04	Ventus Therapeutics U.S., Inc.	Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
MX2022016546A (es)	2020-07-03	2023-02-01	Nihon Nohyaku Co Ltd	Agente anticoccidio y metodo para su uso.
US11319319B1 (en)	2021-04-07	2022-05-03	Ventus Therapeutics U.S., Inc.	Compounds for inhibiting NLRP3 and uses thereof
CN117396467A (zh) *	2021-06-02	2024-01-12	日本农药株式会社	苯并咪唑化合物或其盐类和包含该化合物的犬心丝虫病防治剂及其使用方法
WO2022255460A1 (ja) *	2021-06-02	2022-12-08	日本農薬株式会社	ベンゾイミダゾール化合物又はその塩類及び該化合物を含有する犬糸状虫症防除剤並びにその使用方法
US12331048B2 (en)	2022-10-31	2025-06-17	Ventus Therapeutics U.S., Inc.	Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
JP2025540259A (ja) *	2022-12-08	2025-12-11	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規置換ピラジン－カルボキサミド－イミダゾピリジン誘導体
CN116332855B (zh) *	2023-04-04	2025-08-01	苏州美诺医药科技有限公司	一种crf1受体拮抗剂的苯并咪唑衍生物中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1317266A2 (en) *	2000-08-08	2003-06-11	Ortho-McNeil Pharmaceutical, Inc.	Neuroprotective 2-pyridinamine compositions and related methods
CZ20032691A3 (en) *	2001-03-12	2004-04-14	Avanir Pharmaceuticals	Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
US7105533B2 (en) *	2002-09-13	2006-09-12	Merck & Co., Inc.	Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
CA2555402A1 (en) *	2004-02-12	2005-09-01	Celine Bonnefous	Bipyridyl amides as modulators of metabotropic glutamate receptor-5
CA2561718A1 (en) *	2004-04-13	2005-10-27	Icagen, Inc.	Polycyclic pyridines as potassium ion channel modulators

2008
- 2008-04-17 CA CA002682676A patent/CA2682676A1/en not_active Abandoned
- 2008-04-17 EA EA200901379A patent/EA200901379A1/ru unknown
- 2008-04-17 WO PCT/EP2008/054682 patent/WO2008128968A1/en not_active Ceased
- 2008-04-17 AR ARP080101578A patent/AR068072A1/es unknown
- 2008-04-17 EP EP08736339A patent/EP2146969A1/en not_active Withdrawn
- 2008-04-17 CN CN200880017209A patent/CN101679299A/zh active Pending
- 2008-04-17 MX MX2009011208A patent/MX2009011208A/es not_active Application Discontinuation
- 2008-04-17 AU AU2008240790A patent/AU2008240790A1/en not_active Abandoned
- 2008-04-17 BR BRPI0810653-3A2A patent/BRPI0810653A2/pt not_active Application Discontinuation
- 2008-04-17 KR KR1020097024024A patent/KR20090130141A/ko not_active Withdrawn
- 2008-04-17 JP JP2010503503A patent/JP2010524892A/ja active Pending
- 2008-04-17 PE PE2008000666A patent/PE20090074A1/es not_active Application Discontinuation
- 2008-04-18 US US12/148,557 patent/US20090105266A1/en not_active Abandoned
- 2008-04-18 CL CL2008001114A patent/CL2008001114A1/es unknown
- 2008-04-18 TW TW097114322A patent/TW200904425A/zh unknown

Also Published As

Publication number	Publication date
AU2008240790A1 (en)	2008-10-30
EP2146969A1 (en)	2010-01-27
JP2010524892A (ja)	2010-07-22
PE20090074A1 (es)	2009-03-02
US20090105266A1 (en)	2009-04-23
AR068072A1 (es)	2009-11-04
EA200901379A1 (ru)	2010-04-30
KR20090130141A (ko)	2009-12-17
TW200904425A (en)	2009-02-01
CA2682676A1 (en)	2008-10-30
CN101679299A (zh)	2010-03-24
CL2008001114A1 (es)	2008-12-19
MX2009011208A (es)	2009-10-30
WO2008128968A1 (en)	2008-10-30

Legal Events

Date	Code	Title
2015-06-02	B11A	Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
2015-09-01	B11Y	Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
2022-07-12	B350	Update of information on the portal [chapter 15.35 patent gazette]

Publication	Publication Date	Title
BRPI0810653A2 (pt)	2014-11-04	Derivados de ácido nicotínico como moduladores do receptor metabotrópico de glutamato-5.
BR112012000763A2 (pt)	2018-03-13	derivados de piridin-4-ila
BRPI0817562A2 (pt)	2017-05-02	derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis
BRPI1008948A2 (pt)	2016-03-15	nicotinamida substituída como moduladores kcnq2/3.
EP2404918A4 (en)	2012-08-01	pyridine
BRPI0810202A2 (pt)	2014-10-21	Derivados de piridina
BRPI0914544A2 (pt)	2015-12-15	derivados de pirimidona substituídos
PT2528897E (pt)	2014-11-12	Derivados de piridina dissubstituída como anticancerígenos
BRPI0909527A2 (pt)	2019-09-24	derivados substituídos de 4-aminociclohexano
BR112013015260A2 (pt)	2016-09-13	derivados de enxofre como moduladores de receptor de quimiocina
BRPI0818658A2 (pt)	2015-04-14	Derivados de piridina úteis como ativadores de glicoquinase
DOP2011000086A (es)	2011-04-15	Derivados de acido 1-amino-2-ciclobutiletilboronico
BRPI0918055A2 (pt)	2015-12-01	derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
BRPI0907435A2 (pt)	2015-07-14	Derivados de 5-flúor pirimidina
DE602008003116D1 (de)	2010-12-02	8-oxychinolinderivate als modulatoren des bradykinin-b2-rezeptors
BRPI1013821A2 (pt)	2016-04-05	piridinas substituídas como antagonistas de ccr3.
BRPI1013766A2 (pt)	2016-04-05	"derivados de isoxazol-piridina como moduladores de gaba"
ECSP12011999A (es)	2012-07-31	Derivados benzamida sustituidos
BRPI0810462A2 (pt)	2014-10-14	Derivados de quinolina-carboxamida como antagonistas de p2y12
BRPI0923497A2 (pt)	2019-09-24	derivados de piridazinona
BRPI0915064A2 (pt)	2015-10-27	derivados de qunoxalinadiona
BRPI0910607A2 (pt)	2015-09-22	derivados do ciclohexano espirocíclicos substituídos
BRPI0913832A2 (pt)	2015-10-20	derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0919898A2 (pt)	2016-02-16	4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3
BRPI1014077A2 (pt)	2015-08-25	Derivados de tiazolilperidina como fungicidas